

NDA 19-537/S-038  
NDA 19-847/S-024  
NDA 19-857/S-027  
NDA 19-858/S-021  
NDA 20-780/S-008

Bayer Corporation  
Pharmaceutical Division  
Attention: Andrew S. Verderame  
Associate Director, Regulatory Affairs  
400 Morgan Lane  
West Haven, CT 06416-4175

Dear Mr. Verderame:

Please refer to your supplemental new drug application, NDA 19-537/S-038, dated February 29, 2000, received March 1, 2000, and your supplemental new drug applications, NDAs 19-847/S-024, 19-857/S-027, 19-858/S-021, and 20-780/S-008, dated February 29, 2000, and received March 2, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for CIPRO<sup>®</sup> (ciprofloxacin hydrochloride) Tablets, IV Solution, IV in 5% Dextrose, IV in 0.9% Saline, and Oral Suspension, respectively.

We acknowledge receipt of your submissions dated June 20, June 30, and August 29, 2000 (2).

These supplements provide for the use of CIPRO<sup>®</sup> for inhalational anthrax (post-exposure).

We have completed the review of these supplemental applications, as amended, according to the regulations for accelerated approval, and have concluded that adequate information has been presented to approve CIPRO<sup>®</sup> (ciprofloxacin hydrochloride) Tablets, IV Solution, IV in 5% Dextrose, IV in 0.9% Saline, and Oral Suspension for use as recommended in the agreed upon labeling dated August 29, 2000. Accordingly, these supplemental applications are approved under 21 CFR 314 Subpart H. Approval is effective on the date of this letter. Marketing of these drug products and related activities for the indication of inhalational anthrax (post-exposure) are to be in accordance with the substance and procedures of the referenced accelerated approval regulations.

The final printed labeling (FPL) must be identical to the submitted labeling (text for the oral formulations package insert and text for the IV formulations package insert submitted August 29, 2000).

Please submit 20 paper copies of the FPL as soon as they are available, in no case more than 30 days after they are printed, to each application. Please individually mount ten of the copies on heavy-weight

NDA 19-537/S-038

NDA 19-847/S-024

NDA 19-857/S-027

NDA 19-858/S-021

NDA 20-780/S-008

Page 2

paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic*

*Format - NDAs* (January 1999). For administrative purposes, these submissions should be designated "FPL for approved supplements NDA 19-537/S-038, 20-780/S-008" and "FPL for approved supplements NDA, 19-847/S-024, 19-857/S-027, 19-858/S-021." Approval of these submissions by FDA is not required before the labeling is used.

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further studies to verify and describe clinical benefit. We remind you of your post-marketing study (Subpart H, Phase 4 commitment) specified in your submission dated August 29, 2000. This commitment is:

To cooperate with U.S.-based public health agencies in evaluating data on the use of CIPRO<sup>®</sup> brand of ciprofloxacin in a large U.S. population for inhalational anthrax (post-exposure), should an exposure occur.

Reports should be submitted to these NDAs as supplemental applications. For administrative purposes, all submissions relating to this Phase 4 commitment must be clearly designated "Subpart H, Phase 4 Commitments."

We also remind you that, under 21 CFR 314.550, after the initial 120 day period following the approval of the indication of inhalational anthrax (post-exposure), you must submit all promotional materials for the indication of inhalational anthrax (post-exposure), including promotional labeling as well as advertisements, at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note the pediatric data submitted with these supplements and defer submission of the above-mentioned pediatric requirement for the indication of inhalational anthrax (post-exposure) until January 1, 2004. This submission would consist of the initial study report from your long-term pediatric observational study, as specified in our May 12, 1999 Written Request letter.

NDA 19-537/S-038

NDA 19-847/S-024

NDA 19-857/S-027

NDA 19-858/S-021

NDA 20-780/S-008

Page 3

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Valerie Jensen, R.Ph., Regulatory Project Manager, at (301) 827-2127.

Sincerely,

Dianne Murphy, M.D.

Director

Office of Drug Evaluation IV

Center for Drug Evaluation and Research

NDA 19-537/S-038

NDA 19-847/S-024

NDA 19-857/S-027

NDA 19-858/S-021

NDA 20-780/S-008

Page 4